Benzinga · Feb 20, 2026
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
DW
NASDAQ · DWTX
Dogwood Therapeutics, Inc.
Healthcare · Biotechnology
$1.22
Down-$0.12 (-9.84%)
Updated Nov 3, 2026, 3:04 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.96M
- P/E ratio
- -0.31
- Dividend yield
- 0.00%
- 52-week range
- $1.07 – $7.04
- Volume
- 39.56K
- Avg. volume
- 758.26K
Price performance · DWTX
DWTX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
DWTX closed at $1.22 after 21 trading sessions, down 19.74% for the selected period.
- Last close
- $1.22
- Period change
- -19.74%
- Period low
- $1.11
- Period high
- $1.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $1.26 | $1.2928 | $1.2001 | $1.22 | 39.56K |
| Oct 30, 2026 | $1.30 | $1.355 | $1.2798 | $1.28 | 62.22K |
| Oct 29, 2026 | $1.24 | $1.3799 | $1.19 | $1.23 | 95.93K |
| Oct 28, 2026 | $1.17 | $1.30 | $1.17 | $1.24 | 56.07K |
| Oct 27, 2026 | $1.11 | $1.175 | $1.10 | $1.16 | 28.56K |
| Oct 26, 2026 | $1.14 | $1.1599 | $1.07 | $1.11 | 39.51K |
| Oct 23, 2026 | $1.15 | $1.2045 | $1.12 | $1.12 | 24.59K |
| Oct 22, 2026 | $1.15 | $1.17 | $1.10 | $1.12 | 64.77K |
| Oct 21, 2026 | $1.14 | $1.21 | $1.13 | $1.17 | 40.04K |
| Oct 20, 2026 | $1.22 | $1.2621 | $1.14 | $1.15 | 50.35K |
| Oct 19, 2026 | $1.40 | $1.40 | $1.18 | $1.21 | 228.51K |
| Oct 16, 2026 | $1.26 | $1.30 | $1.20 | $1.22 | 70.28K |
| Oct 15, 2026 | $1.28 | $1.2935 | $1.182 | $1.25 | 105.41K |
| Oct 14, 2026 | $1.31 | $1.34 | $1.24 | $1.27 | 83.18K |
| Oct 13, 2026 | $1.37 | $1.38 | $1.29 | $1.30 | 110.45K |
| Oct 12, 2026 | $1.42 | $1.4601 | $1.37 | $1.37 | 44.09K |
| Oct 9, 2026 | $1.45 | $1.54 | $1.40 | $1.40 | 66.32K |
| Oct 8, 2026 | $1.48 | $1.48 | $1.41 | $1.41 | 62.62K |
| Oct 7, 2026 | $1.50 | $1.51 | $1.43 | $1.43 | 50.52K |
| Oct 6, 2026 | $1.57 | $1.64 | $1.46 | $1.52 | 127.15K |
| Oct 5, 2026 | $1.50 | $1.72 | $1.45 | $1.52 | 99.97K |
Latest DWTX news
The latest Smart Investors Daily articles mentioning DWTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DWTX research
Overview
Company profile and research snapshot.
Company profile
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 30, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 2, 2026
DWTX: Financing Secures Funding Through Phase 2b Data Readout
By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Financial Update On January 15, 2026, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a registered direct offering and a concurrent private placement. An aggregate of 4,386,037
Yahoo · Feb 2, 2026
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial.
Benzinga · Feb 2, 2026
Dogwood Reaches 50% Enrollment In Ongoing Halneuron Phase 2b Trial
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated -
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
